A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs ATLCAR CD19 (Primary) ; Bendamustine (Primary) ; Fludarabine (Primary) ; Rimiducid (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphomatoid granulomatosis; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 22 Mar 2019 Status changed from not yet recruiting to recruiting.
- 18 Feb 2019 Planned initiation date changed from 30 Jan 2019 to 1 Apr 2019.
- 29 Nov 2018 Planned initiation date changed from 30 Oct 2018 to 30 Jan 2019.